Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis

Mol Genet Genomics. 2015 Apr;290(2):709-25. doi: 10.1007/s00438-014-0956-8. Epub 2014 Dec 4.

Abstract

The previously published data on the association between CYP1A2*1C (rs2069514) and CYP1A2*1F (rs762551) polymorphisms and cancer risk have remained controversial. Hence, we performed a meta-analysis to investigate the association between CYP1A2*1F and CYP1A2*1C polymorphisms and cancer risk under different inheritance models. Overall, significant association was observed between CYP1A2*1F and cancer risk when all the eligible studies were pooled into the meta-analysis (dominant model: OR 1.08, 95 % CI 1.02-1.15; heterozygous model: OR 1.06, 95 % CI 1.01-1.12; additive model: OR 1.07, 95 % CI 1.02-1.13). In the further stratified and sensitivity analyses, for CYP1A2*1F polymorphism, significantly increased lung cancer risk and significantly decreased bladder cancer risk were observed in Caucasians. For CYP1A2*1C polymorphism, no significant association was found in overall and all subgroup analyses. In summary, this meta-analysis suggests that CYP1A2*1F polymorphism is associated with lung cancer and bladder cancer risk in Caucasians.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Cytochrome P-450 CYP1A2 / genetics*
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Humans
  • Lung Neoplasms / genetics*
  • Polymorphism, Single Nucleotide
  • Risk
  • Urinary Bladder Neoplasms / genetics*

Substances

  • CYP1A2 protein, human
  • Cytochrome P-450 CYP1A2